Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma

IF 2.1 2区农林科学 Q1 VETERINARY SCIENCES

Journal of Veterinary Internal Medicine Pub Date : 2024-07-03 DOI:10.1111/jvim.17139

Ashley S. Parker, Jenna H. Burton, Kaitlin M. Curran, Amber Wolf-Ringwall, Douglas H. Thamm

{"title":"Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma","authors":"Ashley S. Parker, Jenna H. Burton, Kaitlin M. Curran, Amber Wolf-Ringwall, Douglas H. Thamm","doi":"10.1111/jvim.17139","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Dogs with lymphoma that fail cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (CHOP) before completion of their protocol are commonly thought to have poor long-term outcome, but no previous studies have evaluated the effect of early relapse on progression-free interval (PFI) or overall survival time (OST) for patients undergoing rescue chemotherapy.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>Correlate rescue treatment outcomes in dogs with multicentric lymphoma with outcomes after 1st-line CHOP chemotherapy.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data were collected from 6 previous retrospective or prospective studies in 187 dogs with multicentric lymphoma that received 1st-line CHOP chemotherapy and then received either lomustine (CCNU), L-asparaginase and prednisone (LAP), or rabacfosadine (RAB, Tanovea), with or without prednisone or L-asparaginase.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The PFI after initiation of CHOP chemotherapy was significantly associated with response rate postprogression, PFI, and postrescue survival time (ST) for both rescue protocols. Immunophenotype (B- vs T-cell) was not significantly associated with response, PFI or OST for LAP but was significantly associated with response and PFI for RAB.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Dogs that experience short PFI during or after 1st-line CHOP chemotherapy had lower response rates to rescue treatment, with shorter PFI and ST. Immunophenotype did not significantly affect outcome with LAP but was associated with PFI for RAB.</p>\n </section>\n </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256168/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17139","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Dogs with lymphoma that fail cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (CHOP) before completion of their protocol are commonly thought to have poor long-term outcome, but no previous studies have evaluated the effect of early relapse on progression-free interval (PFI) or overall survival time (OST) for patients undergoing rescue chemotherapy.

Objective

Correlate rescue treatment outcomes in dogs with multicentric lymphoma with outcomes after 1st-line CHOP chemotherapy.

Methods

Data were collected from 6 previous retrospective or prospective studies in 187 dogs with multicentric lymphoma that received 1st-line CHOP chemotherapy and then received either lomustine (CCNU), L-asparaginase and prednisone (LAP), or rabacfosadine (RAB, Tanovea), with or without prednisone or L-asparaginase.

Results

The PFI after initiation of CHOP chemotherapy was significantly associated with response rate postprogression, PFI, and postrescue survival time (ST) for both rescue protocols. Immunophenotype (B- vs T-cell) was not significantly associated with response, PFI or OST for LAP but was significantly associated with response and PFI for RAB.

Conclusion

Dogs that experience short PFI during or after 1st-line CHOP chemotherapy had lower response rates to rescue treatment, with shorter PFI and ST. Immunophenotype did not significantly affect outcome with LAP but was associated with PFI for RAB.

Abstract Image

查看原文本刊更多论文

多中心淋巴瘤患者在接受环磷酰胺、多柔比星、长春新碱和泼尼松化疗期间或化疗后病情出现早期进展，表明采用抢救方案治疗效果不佳。

背景：通常认为，在完成治疗方案前未能接受环磷酰胺、多柔比星、长春新碱和泼尼松化疗（CHOP）的淋巴瘤患犬的长期预后较差，但之前没有研究评估过早期复发对接受挽救性化疗患者的无进展间期（PFI）或总生存时间（OST）的影响：目的：将多中心淋巴瘤犬的抢救治疗结果与一线CHOP化疗后的结果进行对比：方法：从之前的6项回顾性或前瞻性研究中收集数据，187只多中心淋巴瘤犬接受了一线CHOP化疗，然后接受了洛莫司汀（CCNU）、L-天冬酰胺酶和泼尼松（LAP）或雷巴法定（RAB，Tanovea）治疗，同时接受或不接受泼尼松或L-天冬酰胺酶治疗：结果：在两种抢救方案中，开始CHOP化疗后的PFI与进展后反应率、PFI和抢救后生存时间（ST）显著相关。免疫表型（B 细胞与 T 细胞）与 LAP 的反应、PFI 或 OST 无显著相关性，但与 RAB 的反应和 PFI 有显著相关性：结论：在一线CHOP化疗期间或化疗后PFI较短的犬只对抢救治疗的反应率较低，PFI和ST也较短。免疫表型对 LAP 的疗效没有明显影响，但与 RAB 的 PFI 有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Veterinary Internal Medicine 农林科学-兽医学

CiteScore

4.50

自引率

11.50%

发文量

243

审稿时长

22 weeks

期刊介绍： The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.